Alzheimer’s disease (AD) was a neuronal disease with no completely cure drug [1,2]. Patient with AD suffer from symptoms which required closely attention [2-5]. The important limitations of management include lacking of good and practical diagnostic methods and insufficient choice in medications. The crucial barriers to the discovery or synthesis of effective drug for treatments of AD including AD are caused by integration and simultaneous occurrence of several complex pathologies in the patient’s brain treating at a single pathology is inadequate to
effectively stop or even slow down the disease progression. [6,7]. However, it is not easy to discover or synthesis the drug which combines the appropriate characteristics that enables to act in multi modes of pathogenic sites, exhibits excellent efficacy and safety characteristics in the unique molecule and displays the properties of oral absorption drug and appropriate characteristics of CNS drug in the unique molecule (Table 1). These obstacles have raised the inspiration that if there is a new drug candidate that demonstrates features of multi-targeting action and good safety, it could be an alternative choice for Alzheimer’s treatment.
Submit your manuscript at https://www.scholarscentral.org/submissions/international-pharmacy.html